Phenotypic clusters and survival analyses in interstitial pneumonia with myositis-specific autoantibodies
Main Article Content
Keywords
myositis, autoantibody, cluster analysis, interstitial pneumonia, prognosis
Abstract
Background: Interstitial pneumonia (IP) is one of the common pulmonary complications of idiopathic inflammatory myopathy (IIM), among which myositis-specific autoantibodies (MSAs) are specific for diagnosing and predicting the prognosis of IIM.
Objectives: The study aimed to explore the phenotypic clusters and prognosis of patients with IP and MSA (MSA-IP).
Methods: A total of 178 patients with MSA-IP were prospectively enrolled for analysis. Serum MSAs were detected using Western blotting. Radiological patterns of IP were determined according to the classification of idiopathic IPs. Clusters of patients with MSA-IP were identified using cluster analysis. Predictors for acute/subacute onset, therapeutic response, IP progression and survival were also analyzed.
Results: Patients with MSA-IP were classified into four distinct clusters. Cluster 1 were the elderly with chronic onset, nearly normal oxygenation and good survival. Cluster 2 had dyspnea on exertion and nonspecific IP pattern, with moderate survival. Patients in cluster 3 had chronic onset and were prone to IP progression (OR 2.885). Cluster 4 had multi-systemic involvements, positive anti--melanoma differentiation associated gene 5 antibody, and were prone to acute/subacute onset (OR 3.538) and IP progression (OR 5.472), with poor survival. Corticosteroids combined immunosuppressants showed therapeutic response in MSA-IP (OR 4.303) and had a protective effect on IP progression (OR 0.136).
Conclusions: Four clusters of the patients with MSA-IP suggested the distinct clinical, radiological and prognostic features.
References
2. Fischer A, Antoniou K M ,Brown K K et al. An official European Respiratory Society/American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46(4):976-987.
3. Koo S M ,Uh S T. Treatment of connective tissue disease-associated interstitial lung disease: The pulmonologist's point of view. Korean J Intern Med 2017; 32(4):600-610.
4. Fischer A, West S G, Swigris J J, Brown K K ,du Bois R M. Connective tissue disease-associated interstitial lung disease: A call for clarification. Chest 2010; 138(2):251-256.
5. Le Goff B, Cherin P ,Cantagrel A et al. Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis. Arthritis Rheum 2009; 61(1):108-118.
6. Bohan A ,Peter J B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292(8):403-407.
7. Morisset J, Johnson C, Rich E, Collard H R ,Lee J S. Management of Myositis-Related interstitial lung disease. Chest 2016; 150(5):1118-1128.
8. Labirua A ,Lundberg I E. Interstitial lung disease and idiopathic inflammatory myopathies: Progress and pitfalls. Curr Opin Rheumatol 2010; 22(6):633-638.
9. Mimori T, Nakashima R ,Hosono Y. Interstitial lung disease in myositis: Clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012; 14(3):264-274.
10. Fathi M ,Lundberg I E. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 2005; 17(6):701-706.
11. Fathi M, Vikgren J ,Boijsen M et al. Interstitial lung disease in polymyositis and dermatomyositis: Longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59(5):677-685.
12. Marie I, Hachulla E ,Cherin P et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47(6):614-622.
13. Chen I J, Jan W Y ,Lin C W et al. Interstitial lung disease in polymyositis and dermatomyositis. Clin Rheumatol 2009; 28(6):639-646.
14. Richards T J, Eggebeen A ,Gibson K et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum 2009; 60(7):2183-2192.
15. Tieu J, Lundberg I E ,Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol 2016; 30(1):149-168.
16. Fidler L, Doubelt I, Kandel S, Fisher J H, Mittoo S ,Shapera S. Screening for myositis antibodies in idiopathic interstitial lung disease. Lung 2019; 197(3):277-284.
17. Ghirardello A, Zampieri S ,Tarricone E et al. Clinical implications of autoantibody screening in patients with autoimmune myositis. Autoimmunity 2006; 39(3):217-221.
18. Graham J, Bauer V I ,Newton C A et al. Myositis-specific antibodies identify a distinct interstitial pneumonia with autoimmune features phenotype. Eur Respir J 2020;
19. Tanizawa K, Handa T ,Nakashima R et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med 2017; 127(57-64.
20. Jablonski R, Bhorade S, Strek M E ,Dematte J. Recognition and management of myositis-associated rapidly progressive interstitial lung disease. Chest 2020;
21. van de Velden M, D'Enza A I ,Palumbo F. Cluster correspondence analysis. Psychometrika 2017; 82(1):158-185.
22. Szodoray P, Hajas A ,Kardos L et al. Distinct phenotypes in mixed connective tissue disease: Subgroups and survival. Lupus 2012; 21(13):1412-1422.
23. Travis W D, Costabel U ,Hansell D M et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188(6):733-748.
24. Lundberg I E, Tjarnlund A ,Bottai M et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017; 76(12):1955-1964.
25. Wanger J, Clausen J L ,Coates A et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26(3):511-522.
26. Galiè N, Humbert M ,Vachiery J L et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The joint task force for the diagnosis and treatment of pulmonary hypertension of the european society of cardiology (ESC) and the european respiratory society (ERS): Endorsed by: Association for european paediatric and congenital cardiology (AEPC), international society for heart and lung transplantation (ISHLT). Eur Heart J 2016; 37(1):67-119.
27. Eaden J A, Barber C M, Renshaw S A, Chaudhuri N ,Bianchi S M. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: A two centre retrospective study. Sarcoidosis Vasc Diffuse Lung Dis 2020; 37(2):218-224.
28. George P M, Spagnolo P ,Kreuter M et al. Progressive fibrosing interstitial lung disease: Clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 2020; 8(9):925-934.
29. Hervier B, Devilliers H ,Stanciu R et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: Phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012; 12(2):210-217.
30. Mariampillai K, Granger B ,Amelin D et al. Development of a new classification system for idiopathic inflammatory myopathies based on clinical manifestations and Myositis-Specific autoantibodies. Jama Neurol 2018; 75(12):1528-1537.
31. Hamaguchi Y, Fujimoto M ,Matsushita T et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: Heterogeneity within the syndrome. Plos One 2013; 8(4):e60442.
32. Watanabe K, Handa T ,Tanizawa K et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med 2011; 105(8):1238-1247.
33. Andersson H, Aaløkken T M ,Günther A et al. Pulmonary involvement in the antisynthetase syndrome: A comparative cross-sectional study. J Rheumatol 2016; 43(6):1107-1113.
34. Shi J, Li S ,Yang H et al. Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 2017; 44(7):1051-1057.
35. Smith M, Dalurzo M, Panse P, Parish J ,Leslie K. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology. J Clin Pathol 2013; 66(10):896-903.
36. Park J H, Kim D S ,Park I N et al. Prognosis of fibrotic interstitial pneumonia: Idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175(7):705-711.
37. Moghadam-Kia S, Oddis C V, Sato S, Kuwana M ,Aggarwal R. Anti-Melanoma Differentiation-Associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis. Arthritis Care Res (Hoboken) 2016; 68(5):689-694.
38. Motegi S I, Sekiguchi A ,Toki S et al. Clinical features and poor prognostic factors of anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with rapid progressive interstitial lung disease. Eur J Dermatol 2019; 29(5):511-517.
39. Cottin V, Hirani N A ,Hotchkin D L et al. Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27(150):
40. Cottin V. Treatment of progressive fibrosing interstitial lung diseases: A milestone in the management of interstitial lung diseases. Eur Respir Rev 2019; 28(153):
41. Flaherty K R, Brown K K ,Wells A U et al. Design of the PF-ILD trial: A double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4(1):e212.
Article Sidebar
Article Details
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
